Clinical Specialty Index

Finerenone emerges as the safer choice for CKD patients.

Tenecteplase speeds up stroke thrombolysis compared to alteplase.

New EULAR guidelines redefine RA management with DMARDs.

The 2026 ACC/AHA/Multisociety guideline introduces lower treatment goals, formal risk equations, and mandates Lp(a) assessment for dyslipidemia pharmacists.

The 2026 AHA/ASA guideline replaces the 2018 guideline and its 2019 update, elevating tenecteplase to a co-first-line thrombolytic with alteplase, endorsing imaging-selected thrombolysis out to 9 hours and in wake-up stroke, expanding endovascular thrombectomy to large ischemic cores and basilar occlusion, and reversing intensive glucose and blood-pressure targets.

The A2B trial evaluates sedation strategies on extubation timing in critical care.

DAPA ACT HF-TIMI 68 evaluates dapagliflozin's effect in acute heart failure, finding no short-term risk reduction.

The 2022 AHA/ACC/HFSA guideline redefines heart failure subtypes and updates foundational recommendations for GDMT, SGLT2 inhibitors, and phenotype-directed care.

The BTF 4th Edition revises hyperosmolar, seizure, steroid, ICP-threshold, and sedation guidance most relevant to neuro-ICU pharmacists.

Early LAI use in schizophrenia improves outcomes and adherence.

Venetoclax levels spike with posaconazole: TDM is essential.

Does prior thrombolysis influence thrombectomy effectiveness in stroke recovery?

Optimize vancomycin dosing with precision models in young patients.

Nanocarriers show potential for improving epilepsy drug delivery.

Chemo-immunotherapy may enable less invasive breast cancer surgeries.